• 1
    Schwartz GF, Giuliano AE, Veronesi U, the Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 25422551.
  • 2
    SobinLH, WittekindC (eds.). TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, 2002.
  • 3
    Roumen RM, Pijpers HJ, Thunnissen FB, Ruers TJ. [Summary of the guideline ‘Sentinel node biopsy in breast cancer.’ Dutch Work Group ‘Sentinel Node Biopsy for Breast Cancer’]. Ned Tijdschr Geneeskd. 2000; 144: 18641867.
  • 4
    Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res. 2004; 6: 165169.
  • 5
    Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001; 92: 13781384.
  • 6
    den Bakker MA, van Weeszenberg A, De Kanter AY, et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol. 2002; 55: 932935.
  • 7
    Liu LH, Siziopikou KP, Gabram S, McClatchey KD. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med. 2000; 124: 16701673.
  • 8
    Jakub JW, Diaz NM, Ebert MD, et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg. 2002; 184: 302306.
  • 9
    Cserni G. Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol. 2002; 55: 926931.
  • 10
    Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol. 2001; 8: 675681.
  • 11
    Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003; 98: 23072315.
  • 12
    Joseph KA, El Tamer M, Komenaka I, Troxel A, Ditkoff BA, Schnabel F. Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis. Arch Surg. 2004; 139: 648651.
  • 13
    Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999; 17: 17201726.
  • 14
    Gray RJ, Pockaj BA, Conley CR. Sentinel lymph node metastases detected by immunohistochemistry only do not mandate complete axillary lymph node dissection in breast cancer. Ann Surg Oncol. 2004; 11: 10561060.
  • 15
    Bader AA, Tio J, Petru E, et al. T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat. 2002; 76: 1117.
  • 16
    Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000; 89: 574581.
  • 17
    Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001; 8: 145149.
  • 18
    Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003; 10: 248254.
  • 19
    Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005; 241: 319325.
  • 20
    Nieweg OE, Jansen L, Valdes Olmos RA, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med. 1999; 26: 1116.
  • 21
    Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003; 39: 16541667.
  • 22
    Nieweg OE, van Rijk MC, Valdes Olmos RA, Hoefnagel CA. Sentinel node biopsy and selective lymph node clearance-impact on regional control and survival in breast cancer and melanoma. Eur J Nucl Med Mol Imaging. 2005; 32: 631634.
  • 23
    Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005; 103: 15811586.
  • 24
    Cox C, Vrcel V, Riker A, et al. Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer. Newsletter San Antonio Breast Cancer Symposium, Issue 3, December 10, 2005
  • 25
    Rutgers EJ. Sentinel node micrometastasis in breast cancer. Br J Surg. 2004; 91: 12411242.
  • 26
    Schroder CP, Ruiters MH, De Jong S, et al. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer. 2003; 106: 611618.
  • 27
    Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: Implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001; 20: 230237.
  • 28
    Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004; 22: 97101.